

# Peter Sundström

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8881434/publications.pdf>

Version: 2024-02-01

27  
papers

1,978  
citations

623188

14  
h-index

580395

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

3294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
2	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237.	1.5	307
3	Rituximab in multiple sclerosis. <i>Neurology</i> , 2016, 87, 2074-2081.	1.5	278
4	Vitamin D as a protective factor in multiple sclerosis. <i>Neurology</i> , 2012, 79, 2140-2145.	1.5	192
5	Venous and cerebrospinal fluid flow in multiple sclerosis: A case-control study. <i>Annals of Neurology</i> , 2010, 68, 255-259.	2.8	167
6	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16955-16960.	3.3	120
7	Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 215, 102-107.	1.1	89
8	Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. <i>Neurology</i> , 2016, 87, 141-147.	1.5	74
9	Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 2715.	2.2	63
10	Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1587-1591.	1.4	49
11	Effect of high-dose vitamin D <sup>3</sup> supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 395-402.	1.4	43
12	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 462-468.	1.0	21
13	Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2161-2168.	1.8	21
14	Vitamin D and multiple sclerosis: where do we go from here?. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 9-18.	1.4	19
15	Leptin levels are associated with multiple sclerosis risk. <i>Multiple Sclerosis Journal</i> , 2021, 27, 19-27.	1.4	17
16	Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. <i>PLoS ONE</i> , 2018, 13, e0192516.	1.1	13
17	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982659.	0.5	11
18	High serum concentration of vitamin D may protect against multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989229.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1532-1539.	1.4	8
20	Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103288.	0.9	8
21	The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1137-1147.	1.4	6
22	Viremia preceding multiple sclerosis: Two nested case-control studies. <i>Virology</i> , 2018, 520, 21-29.	1.1	3
23	Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560820.	0.5	2
24	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 161-168.	1.0	2
25	How to minimize the risk for headache? A lumbar puncture practice questionnaire study = Hogyan csökkenthetők a posztpunkciós fejfájások? Kérdéses vizsgálat a lumbálpunkciós gyakorlatról. <i>Ideggyógyászati Szemle</i> , 2016, 69, 397-402.	0.4	2
26	Response to Mendelian randomization analysis does not support a role for leptin in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 161-162.	1.4	0
27	Incidence and Prevalence of Multiple Sclerosis in Malmö, Southern Sweden. <i>Multiple Sclerosis International</i> , 2022, 2022, 1-7.	0.4	0